Xenon Pharmaceuticals Inc. (XENE)

NASDAQ: XENE · IEX Real-Time Price · USD
43.13
+0.13 (0.30%)
Mar 28, 2024, 3:59 PM EDT - Market closed

Company Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.

It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy.

The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals logo
Country Canada
Founded 1996
IPO Date Nov 5, 2014
Industry Biotechnology
Sector Healthcare
Employees 259
CEO Ian C. Mortimer C.M.A., CPA, M.B.A.

Contact Details

Address:
200 - 3650 Gilmore Way
Burnaby, A1 V5G 48W
British Columbia, Canada
Phone (604) 484-3300
Website xenon-pharma.com

Stock Details

Ticker Symbol XENE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001582313
CUSIP Number 98420N105
ISIN Number CA98420N1050
Employer ID 98-0661854
SIC Code 2834

Key Executives

Name Position
Ian C. Mortimer C.M.A., CPA, M.B.A. President, Chief Executive Officer and Director
Sherry Aulin Chief Financial Officer
Andrea DiFabio J.D. Chief Legal Officer and Corporate Secretary
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. Chief Commercial Officer
Dr. Christopher John Kenney M.D. Chief Medical Officer
Shelley McCloskey B.A. Executive Vice President of Human Resources
Dr. Robin P. Sherrington Ph.D. Executive Vice President of Strategy and Innovation
Dr. James R. Empfield Ph.D. Executive Vice President of Drug Discovery
Sheila M. Grant M.B.A., M.Sc., MBA Executive Vice President of Research & Development Operations

Latest SEC Filings

Date Type Title
Mar 8, 2024 144 Filing
Mar 8, 2024 8-K Current Report
Mar 7, 2024 144 Filing
Mar 7, 2024 144 Filing
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals